Literature DB >> 33682430

Protocol for Digital Real-world Evidence trial for Adults with insomnia treated via Mobile (DREAM): an open-label trial of a prescription digital therapeutic for treating patients with chronic insomnia.

Frances P Thorndike1, Richard B Berry2, Robert Gerwien1, Stephen Braun1, Yuri A Maricich1.   

Abstract

Background: Cognitive behavioral therapy for insomnia (CBT-I) is underused in healthcare settings and is challenging for people with insomnia to access because of uneven geographical distribution of behavioral sleep medicine providers. Prescription digital therapeutics can overcome these barriers. This study evaluates the effectiveness of a specific digital CBT-I therapeutic. Materials & methods: Digital Real-world Evidence trial for Adults with insomnia treated via Mobile (DREAM) is a 9-week, open-label, decentralized clinical trial to collect real-world evidence for a digital therapeutic (Somryst™) delivering CBT-I to patients with chronic insomnia. The primary objective is to examine the effectiveness of Somryst to reduce self-reported insomnia symptoms and severity in a real-world population (n = 350).
Conclusion: This pragmatic study seeks to assess the potential benefits of treating insomnia with an asynchronous, mobile, tailored prescription digital therapeutic. Clinical trial registration: NCT04325464 (ClinicalTrials.gov).

Entities:  

Keywords:  CBT-I; PDT; chronic insomnia; cognitive behavioral therapy for insomnia; digital therapeutics; insomnia; prescription digital therapeutic

Mesh:

Year:  2021        PMID: 33682430     DOI: 10.2217/cer-2021-0004

Source DB:  PubMed          Journal:  J Comp Eff Res        ISSN: 2042-6305            Impact factor:   1.744


  1 in total

1.  PreScription DigitaL ThErapEutic for Patients with Insomnia (SLEEP-I ): a protocol for a pragmatic randomised controlled trial.

Authors:  Rachel P Dreyer; Alyssa Berkowitz; Henry Klar Yaggi; Lynelle Schneeberg; Nilay D Shah; Lindsay Emanuel; Bhanuprakash Kolla; Molly Moore Jeffery; Mark Deeg; Keondae Ervin; Frances Thorndike; Joseph S Ross
Journal:  BMJ Open       Date:  2022-08-08       Impact factor: 3.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.